iXgene Inc. (Head office: Shinjuku-ku, Tokyo; President: Toshiharu Furukawa) has signed an agreement with Keio University Educational Corporation (President: Kohei Ito) to obtain an exclusive license for commercialization of the suicide gene-transfected iPS cell patents.